BioMarin Pharmaceutical Inc. (BMRN) M&A Call Transcript

SA Transcripts157.42K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call BioMarin Pharmaceutical Inc. (BMRN) M&A Call December 19, 2025 8:15 AM EST Company Participants Traci McCarty - Group Vice PresidentAlexander Hardy - President, CEO & DirectorBrian Mueller - Executive VP of Finance, CFO & Principal Accounting Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald & Co., Research Division Presentation Operator Thank you for standing by. My name is Jayel, and I will be your conference operator today. At this time, I would like to welcome everyone to the BioMarin business update. [Operator Instructions] I would now like to turn the conference over to Traci McCarthy, Head of Investor Relations. You may begin. Perhaps, your line is on mute, Traci. Traci McCartyGroup Vice President Thank you, Jayel, and good morning, everyone. Thank you for joining us to discuss BioMarin's acquisition of Amicus Therapeutics, expanding BioMarin's position as a leader in rare diseases and creating value for shareholders from day 1. Please find our press release and PowerPoint on the Investor Relations section of the website. Moving to Slide 2, our forward-looking statements. This call is being recorded, and a press release and slide presentation are now available. I would like to direct you to our safe harbor statement, which in summary says that we will be making forward-looking statements through the course of our discussion today, and actual results may differ materially. Moving to the agenda on Slide 3. Joining the call today from BioMarin is our CEO, Alexander Hardie; and CFO, Brian Mueller. Joining us for the Q&A portion of the call are Kristin Hubbard, BioMarin's Chief Commercial Officer; and Greg Freiberg, BioMarin's Chief R&D Officer. With that, I will turn the call over to you, Alexander. Alexander HardyPresident, CEO & Director Thank you, Traci, and thank you for joining our call on what is an important